For rapid and simple collection, and preservation of urine samples
For research use only and NOT intended for in vitro diagnostics.
For rapid and simple collection, and preservation of urine samples
Register today to receive an exclusive 15% off* on your first order.
Norgen's Urine Preservative is designed for the rapid preservation of DNA, RNA, microRNA and proteins from fresh urine samples. In addition, the Urine Preservative eliminates the need to immediately process or freeze samples and allows the samples to be shipped to centralized testing facilities at ambient temperatures. The components of the Urine Preservative allow samples to be stored for over 2 years at room temperature with no detected degradation of urine DNA, RNA or proteins.
Norgen's Urine Preservative is available in 2 convenient formats:
1. Urine Preservative Single Dose Ampules
With this product Norgen's Urine Preservative is supplied in a liquid format in single dose ampules. The user simply collects 5 - 50 mL of urine into a urine collection container and adds the contents of the Urine Preservative Single Dose (Cat# 18126). The urine and preservative are then mixed, and the urine nucleic acids and proteins are preserved at room temperature.
2. Urine Collection and Preservation Tubes
Norgen's Urine Preservative is also available in a dried format in Norgen’s Urine Collection and Preservation Tubes. The user simply collects urine into the tubes and mixes gently until the orange preservative pellet in the tube has dissolved. Norgen's Urine Collection and Preservation Tubes are available in 3 convenient sizes:
Figure 1. Stability of DNA in Norgen's Urine Preservative. Urine samples were collected from numerous healthy donors and pooled, and then the urine was aliquoted into 5 mL aliquots in Norgen's Urine Collection and Preservation Tubes (5 cc) (Cat# 18116). The preserved urine was stored at -20°C, 4°C and room temperature for up to 48 months. Urine DNA was subsequently isolated at time 0, 1 month, 2 months, 4 months, 8 months, 12 months, 16 months, 20 months and 24 months from the preserved urine using Norgen's Urine DNA Isolation Kit (Slurry Format) (Cat# 48800). To test the integrity of the purified DNA, 3 μL of each elution was used in a 20 μL Taqman PCR reaction run on a CFX96 Touch Real-Time PCR Detection System (Bio-Rad) using Norgens 2X PCR Master Mix with 5s rRNA primers. As it can be seen, all the DNA samples were successfully amplified. Furthermore, the quality of the concentrated and preserved urine DNA stored at all 3 temperatures did not significantly change from 0 months to 24 months, as indicated by the fact that the Ct value remained consistent.
Figure 2. Stability of RNA in Norgen's Urine Preservative. Urine samples were collected from numerous healthy donors and pooled, and then the urine was aliquoted into 5 mL aliquots in Norgen's Urine Collection and Preservation Tubes (5 cc) (Cat. 18116). The preserved urine was stored at -20°C, 4°C, and room temperature for up to 24 months. Urine RNA was then subsequently isolated at time 0, 1 month, 2 months, 4 months, 8 months, 12 months, 16 months, and 24 months from the preserved urine using Norgen's Urine Total RNA Purification Maxi Kit (Slurry Format) (Cat. 29600).
Select Urine Tested with the Norgen Urine Collection and Preservation Tubes
Available Sizes and Formats
Storage Conditions and Product Stability
All tubes should be kept tightly sealed and stored at room temperature (15 – 25°C) for up to 2 years without any reduction in performance.
| Kit Components | Cat. 18118 (50 tubes) | Cat. 18122 (50 tubes) | Cat. 18113 (50 tubes) | Cat. 18126 (50 tubes) | Cat. 18129 (1 cup) |
|---|---|---|---|---|---|
| Urine Collection and Preservation Tubes (5 cc) | 50 | - | - | - | - |
| Urine Collection and Preservation Tubes (15 cc) | - | 50 | - | - | - |
| Urine Collection and Preservation Tubes (50 cc) | - | - | 50 | - | - |
| Urine Preservative Single Dose | - | - | - | 50 | - |
| Urine Collection and Preservation Cup (120 cc) | - | - | - | - | 1 |
| ID Labels | 50 | - | - | 50 | - |
| Product Insert | 1 | 1 | 1 | 1 | 1 |
| Title | PD-L1 as a Urine Biomarker in Renal Cell Carcinoma—A Case Series and Proof-of-Concept Study |
| Citation | Diagnostics 2024. |
| Authors | Philipp Reimold 1,†,Georgi Tosev 1,Adam Kaczorowski 2,Jana Friedhoff 2,Constantin Schwab 3ORCID,Viktoria Schütz 1ORCID,Magdalena Görtz 1ORCID,Niklas Panzer 1,Martina Heller 1,Cem Aksoy 1ORCID,Ruth Himmelsbach 1,Thomas Walle 4ORCID,Stefanie Zschäbitz 4,Dirk Jäger 4,Anette Duensing 1,5ORCID,Albrecht Stenzinger 3,Markus Hohenfellner 1 andStefan Duensing 1,2,* |
| Title | Risk Classification for Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) Using Machine Learning Based Predictions |
| Citation | Urology 2024. |
| Authors | Laura E. Lamb a b, Joseph J. Janicki c, Sarah N. Bartolone d, Elijah P. Ward d, Nitya Abraham e, Melissa Laudano e, Christopher P. Smith f, Kenneth M. Peters a d c, Bernadette M.M. Zwaans a d, Michael B. Chancellor |
| Title | Accurate Detection of Urothelial Bladder Cancer Using Targeted Deep Sequencing of Urine DNA |
| Citation | Cancers 2023. |
| Authors | Dongin Lee, Wookjae Lee, Hwang-Phil Kim, Myong Kim, Hyun Kyu Ahn, Duhee Bang and Kwang Hyun Kim |
| Title | Highly Sensitive and Specific Detection of Bladder Cancer via Targeted Ultra-deep Sequencing of Urinary DNA |
| Citation | European urology oncology 2023. |
| Authors | Douglas G. Ward, Laura Baxter, Sascha Ott, Naheema S. Gordon, Junhui Wang, Prashant Patel, Kim Piechocki, Lee Silcock, Chris Sale, Maurice P. Zeegers, K.K. Cheng, Nicholas D. James, Richard T. Bryan, BladderPath Trial Management Group |
| Title | Postradiotherapy Urinary Extracellular Vesicle Concentrations Predict Late Bladder Toxicity in Patients with Prostate Cancer |
| Citation | JU Open Plus 2023. |
| Authors | Molony, Ryan; Kerns, Sarah L; Marples, Brian; Oshodi, Emmanuel; Chen, YuhChyau; Lee, Yi-Fen |
| Title | A prospective multicenter study on bladder cancer: the COBLAnCE cohort |
| Citation | BMC Cancer 2016. |
| Authors | Benhamou, S., Bonastre, J., Groussard, K., Radvanyi, F., Allory, Y., & Lebret, T |
| Title | Effects of hexanic extract of serenoa repens (permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia |
| Citation | The Prostate 2015. |
| Authors | A Latil, M Pétrissans, J Rouquet, G Robert, A de la Taille |
| Title | Long Noncoding RNAs as Putative Biomarkers for Prostate Cancer Detection |
| Citation | The Journal of Molecular Diagnostics 2014. |
| Authors | B Lee, J Mazar, MN Aftab, F Qi, J Shelley, JL Li, S Govindarajan, F Valerio, I Rivera, T Thum, TA Tran, D Kameh, V Patel, RJ Perera |
| Title | Detection of specifi chrmosomal aberrations in urine using BCA-1 (oligo-CGH-array) enhances diagnostic sensitivity and predicts the aggressiveness of non-muscle-invasive bladder transitional cell carcinoma |
| Citation | World Journal of Urology 2013. |
| Authors | O Cussenot, K Sighar, M Mohammed, S Hugonin, V Ondet, S Larre, R Lacave, M Roupret, G Cancel-Tassin |